Success Rates of Clomiphene Citrate and Recombinant Gonadotropin Cycles: A Single-Center Experience

Success Rates of Clomiphene Citrate and Recombinant Gonadotropin Cycles: A Single-Center Experience

Blog Article

Objective: This aim of this study is Angel Wing Headstall and Breast Collar Sets to assess the ovulation induction cycles based on clomiphene citrate and gonadotropin administration and specify the factors associated with successful outcomes.Study Design: This is a prospective study of 631 patients who underwent 917 ovulation induction cycles.While clomiphene citrate was used in 680 cycles (74.2%) and recombinant follicle-stimulating hormone was administered in 237 cycles (25.

8%).Results: A total of 153 pregnancies were achieved in 917 ovulation induction cycles, indicating a clinical pregnancy rate of 16.7%.The ovulation induction cycles which ended up with clinical pregnancy had a significantly lower frequency of smoking (p=0.

005), shorter infertility duration (p=0.001), higher basal luteinizing hormone (p=0.021) and lower basal progesterone (p=0.008) than unsuccessful cycles.

The clomiphene citrate cycles which ended up with clinical pregnancy had a significantly lower frequency of smoking (p=0.011), shorter infertility duration (p=0.001) and lower basal progesterone (p=0.013) than the unsuccessful cycles.

The recombinant follicle-stimulating hormone cycles which ended up with clinical pregnancy had a significantly higher basal luteinizing hormone (p=0.008) than the Counter Height Side Chair unsuccessful cycles.Basal luteinizing hormone and progesterone concentrations could significantly distinguish the patients who were able to conceive in ovulation induction cycles (p=0.021 and p=0.

008, respectively).Conclusions: Smoking, longer duration of infertility, and elevated basal progesterone are poor prognostic factors for clinical pregnancy in clomiphene citrate and recombinant follicle-stimulating hormone cycles.